Showing results (21-30 of 102) with videos related to
Sort By:
Pageof 11
Cancer Treatment and Research Communications|September 29, 2022
The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinomaAndrew W Hahn, Justin Lebenthal, Giannicola Genovese, et al.Current Treatment Options in Oncology|February 22, 2018
The Role of Circulating Tumor DNA in Renal Cell CarcinomaPaulo G Bergerot, Andrew W Hahn, Cristiane Decat Bergerot, et al.Journal of Geriatric Oncology|June 5, 2018
Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysisPeter Hale, Andrew W Hahn, Nityam Rathi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal PelvisAndrew W Hahn, Smith Giri, Dilan Patel, et al.Blood Reviews|August 1, 2015
Acute megakaryocytic leukemia: What have we learnedAndrew W Hahn, Bojia Li, Philippe Prouet, et al.Clinical Lymphoma, Myeloma & Leukemia|September 21, 2015
How Center Volumes Affect Early Outcomes in Acute Myeloid LeukemiaAndrew W Hahn, Omer Jamy, Sara Nunnery, et al.Clinical Genitourinary Cancer|June 3, 2018
Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell CarcinomaAndrew W Hahn, Camryn Froerer, Sidney VanAlstine, et al.Clinical Genitourinary Cancer|April 21, 2018
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate CancerAndrew W Hahn, David M Gill, Roberto H Nussenzveig, et al.Cancer Treatment and Research Communications|February 12, 2019
Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and timeAndrew W Hahn, David Stenehjem, Roberto Nussenzveig, et al.Clinical Genitourinary Cancer|September 30, 2017
Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate CancerAustin Poole, David Gill, Andrew W Hahn, et al.Pageof 11